Cargando…
Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care
Multidisciplinary team (MDT) meetings are becoming the model of care for cancer patients worldwide. While MDTs have improved the quality of cancer care, the meetings impose substantial time pressure on the members, who generally attend several such MDTs. We describe Lung Cancer Assistant (LCA), a cl...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233704/ https://www.ncbi.nlm.nih.gov/pubmed/24990290 http://dx.doi.org/10.1098/rsif.2014.0534 |
_version_ | 1782344767145771008 |
---|---|
author | Sesen, M. Berkan Peake, Michael D. Banares-Alcantara, Rene Tse, Donald Kadir, Timor Stanley, Roz Gleeson, Fergus Brady, Michael |
author_facet | Sesen, M. Berkan Peake, Michael D. Banares-Alcantara, Rene Tse, Donald Kadir, Timor Stanley, Roz Gleeson, Fergus Brady, Michael |
author_sort | Sesen, M. Berkan |
collection | PubMed |
description | Multidisciplinary team (MDT) meetings are becoming the model of care for cancer patients worldwide. While MDTs have improved the quality of cancer care, the meetings impose substantial time pressure on the members, who generally attend several such MDTs. We describe Lung Cancer Assistant (LCA), a clinical decision support (CDS) prototype designed to assist the experts in the treatment selection decisions in the lung cancer MDTs. A novel feature of LCA is its ability to provide rule-based and probabilistic decision support within a single platform. The guideline-based CDS is based on clinical guideline rules, while the probabilistic CDS is based on a Bayesian network trained on the English Lung Cancer Audit Database (LUCADA). We assess rule-based and probabilistic recommendations based on their concordances with the treatments recorded in LUCADA. Our results reveal that the guideline rule-based recommendations perform well in simulating the recorded treatments with exact and partial concordance rates of 0.57 and 0.79, respectively. On the other hand, the exact and partial concordance rates achieved with probabilistic results are relatively poorer with 0.27 and 0.76. However, probabilistic decision support fulfils a complementary role in providing accurate survival estimations. Compared to recorded treatments, both CDS approaches promote higher resection rates and multimodality treatments. |
format | Online Article Text |
id | pubmed-4233704 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | The Royal Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-42337042014-11-21 Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care Sesen, M. Berkan Peake, Michael D. Banares-Alcantara, Rene Tse, Donald Kadir, Timor Stanley, Roz Gleeson, Fergus Brady, Michael J R Soc Interface Research Articles Multidisciplinary team (MDT) meetings are becoming the model of care for cancer patients worldwide. While MDTs have improved the quality of cancer care, the meetings impose substantial time pressure on the members, who generally attend several such MDTs. We describe Lung Cancer Assistant (LCA), a clinical decision support (CDS) prototype designed to assist the experts in the treatment selection decisions in the lung cancer MDTs. A novel feature of LCA is its ability to provide rule-based and probabilistic decision support within a single platform. The guideline-based CDS is based on clinical guideline rules, while the probabilistic CDS is based on a Bayesian network trained on the English Lung Cancer Audit Database (LUCADA). We assess rule-based and probabilistic recommendations based on their concordances with the treatments recorded in LUCADA. Our results reveal that the guideline rule-based recommendations perform well in simulating the recorded treatments with exact and partial concordance rates of 0.57 and 0.79, respectively. On the other hand, the exact and partial concordance rates achieved with probabilistic results are relatively poorer with 0.27 and 0.76. However, probabilistic decision support fulfils a complementary role in providing accurate survival estimations. Compared to recorded treatments, both CDS approaches promote higher resection rates and multimodality treatments. The Royal Society 2014-09-06 /pmc/articles/PMC4233704/ /pubmed/24990290 http://dx.doi.org/10.1098/rsif.2014.0534 Text en http://creativecommons.org/licenses/by/3.0/ © 2014 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original author and source are credited. |
spellingShingle | Research Articles Sesen, M. Berkan Peake, Michael D. Banares-Alcantara, Rene Tse, Donald Kadir, Timor Stanley, Roz Gleeson, Fergus Brady, Michael Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care |
title | Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care |
title_full | Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care |
title_fullStr | Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care |
title_full_unstemmed | Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care |
title_short | Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care |
title_sort | lung cancer assistant: a hybrid clinical decision support application for lung cancer care |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233704/ https://www.ncbi.nlm.nih.gov/pubmed/24990290 http://dx.doi.org/10.1098/rsif.2014.0534 |
work_keys_str_mv | AT sesenmberkan lungcancerassistantahybridclinicaldecisionsupportapplicationforlungcancercare AT peakemichaeld lungcancerassistantahybridclinicaldecisionsupportapplicationforlungcancercare AT banaresalcantararene lungcancerassistantahybridclinicaldecisionsupportapplicationforlungcancercare AT tsedonald lungcancerassistantahybridclinicaldecisionsupportapplicationforlungcancercare AT kadirtimor lungcancerassistantahybridclinicaldecisionsupportapplicationforlungcancercare AT stanleyroz lungcancerassistantahybridclinicaldecisionsupportapplicationforlungcancercare AT gleesonfergus lungcancerassistantahybridclinicaldecisionsupportapplicationforlungcancercare AT bradymichael lungcancerassistantahybridclinicaldecisionsupportapplicationforlungcancercare |